Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 20/20 | 0.66 |
| ▸ | HSP90AB1 | P08238 | 19/20 | 0.66 |
| ▸ | TRAP1 | Q12931 | 2/20 | 0.49 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1790794 | 0.99 | HSP90AA1 (0.67) | HSP90AA1HSP90AB1TRAP1HSP90B1 | |
| SCHEMBL12613739 | 0.97 | HSP90AA1 (0.67) | HSP90AA1HSP90AB1TRAP1HSP90B1 | |
| SCHEMBL12613735 | 0.91 | HSP90AA1 (0.64) | HSP90AA1HSP90AB1TRAP1HSP90B1 | |
| SCHEMBL1789517 | 0.87 | HSP90AA1 (0.70) | HSP90AA1HSP90AB1TRAP1HSP90B1 | |
| SCHEMBL1787200 | 0.85 | HSP90AA1 (0.68) | HSP90AA1HSP90AB1TRAP1HSP90B1 | |
| SCHEMBL13539714 | 0.80 | HSP90AA1 (0.71) | HSP90AA1HSP90AB1TRAP1HSP90B1 | |
| SCHEMBL1060173 | 0.79 | HSP90AA1 (1.00) | HSP90AA1HSP90AB1TRAP1HSP90B1 | |
| SCHEMBL1059089 | 0.78 | HSP90AA1 (0.68) | HSP90AA1HSP90AB1TRAP1HSP90B1 | |
| SCHEMBL12614244 | 0.78 | HSP90AA1 (0.39) | HSP90AA1HSP90AB1TRAP1HSP90B1 | |
| SCHEMBL12613946 | 0.78 | HSP90AA1 (0.62) | HSP90AA1HSP90AB1TRAP1HSP90B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110124634-A1 | BIOACTIVE COMPOUNDS FOR TREATMENT OF CANCER AND NEURODEGENERATIVE DISEASES | PONIARD PHARMACEUTICALS, INC. | 2011-05-26 | — | — | US | disclosed |
| US-20110124634-A1 | BIOACTIVE COMPOUNDS FOR TREATMENT OF CANCER AND NEURODEGENERATIVE DISEASES | PONIARD PHARMACEUTICALS, INC. | 2011-05-26 | — | — | US | disclosed |
| US-20110124634-A1 | BIOACTIVE COMPOUNDS FOR TREATMENT OF CANCER AND NEURODEGENERATIVE DISEASES | PONIARD PHARMACEUTICALS, INC. | 2011-05-26 | — | — | US | disclosed |
| WO-2009139834-A1 | BIOACTIVE COMPOUNDS FOR TREATMENT OF CANCER AND NEURODEGENERATIVE DISEASES | PONIARD PHARMACEUTICALS, INC. (US) | 2009-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124634-A1 | BIOACTIVE COMPOUNDS FOR TREATMENT OF CANCER AND NEURODEGENERATIVE DISEASES | PARK7, BDNF, BACE1 | HSP90AA1 1418/4885HSP90AB1 667/4885TRAP1 443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.